David McSorley

Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial

Michael Camilleri, Allison R. Northcutt, Steven Kong et al. · The Lancet · 2000 · 558 citations

Functional Gastrointestinal Disorder, Gastrointestinal Pharmacology, Medicine +4

Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5‐HT₃ receptor antagonist

Camilleri, Mayer, Drossman et al. · Alimentary Pharmacology & Therapeutics · 1999 · 372 citations · Full text

A Randomized Controlled Clinical Trial of the Serotonin Type 3 Receptor Antagonist Alosetron in Women With Diarrhea-Predominant Irritable Bowel Syndrome

Michael Camilleri, William Y. Chey, Emeran A. Mayer et al. · Archives of Internal Medicine · 2001 · 304 citations

Helicobacter Pylori Infection Rates in Duodenal Ulcer Patients in The United States May Be Lower Than Previously Estimated

Arthur A. Ciociola, David McSorley, K. Turner et al. · The American Journal of Gastroenterology · 1999 · 246 citations

A Dose-Ranging, Phase II Study of the Efficacy and Safety of Alosetron in Men with Diarrhea-Predominant IBS

Lin Chang, Vanessa Z. Ameen, George E. Dukes et al. · The American Journal of Gastroenterology · 2005 · 140 citations